India hits 400,000 virus deaths as vaccinations slow
India became the third country to pass 400,000 Covid-19 deaths, official data showed Friday, as the country's vast vaccination drive slows.
Total deaths are 400,312, according to the health ministry -- behind only the United States and Brazil -- with total cases almost 30.5 million.
Many experts suspect India's true death toll is more than a million, after a devastating spike in cases in April and May that overwhelmed hospitals.
The surge was blamed on the Delta variant and government complacency after Prime Minister Narendra Modi declared victory over the virus in January.
Daily case numbers have since decreased significantly and many restrictions on activity have been lifted, raising fears of a new spike in coming months.
The government aims to vaccinate all of the country's 1.1 billion adults this year. But because of shortages, administrative confusion and hesitancy, only around five percent have had two doses so far.
On June 21 the government tried to jumpstart the drive by making vaccines free for all adults, leading to a surge in demand with more than nine million shots being given in a day.
Daily inoculation rates have since slowed again, however, averaging just over four million per day over the past week, according to government figures.
A government affidavit filed with the Supreme Court this week slashed the number of doses the government expects to be available between August and December to 1.35 billion, from a previous projection of 2.16 billion, according to media reports.
The filing mentioned five kinds of vaccine, down from eight in its forecast in May, the reports said, and cut the number of predicted AstraZeneca doses to 500 million from 750 million previously.
On Tuesday India approved the Moderna vaccine for domestic use, taking to four the number available along with AstraZeneca, Bharat Biotech's Covaxin and Russia's Sputnik V.
Indian drugmaker Zydus Cadila on Thursday said it had applied for approval for its plasmid DNA-based vaccine after trials showed an efficacy rate of 67 percent.
Cadila chief Sharvil Patel told a news conference the firm hoped to produce 50 million doses by the end of the year with monthly output of 10 million.